InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,973.10
(
0.74%
)
US TECH 100
20,554.80
(
1.64%
)
Dow Jones
43,729.34
(
0.00%
)
Brent Oil
75.24
(
-0.30%
)
Bitcoin
75,880.35
(
-0.03%
)
Post# of 43443
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (6) Keep Next 10 Report Keyboard Shortcuts
Replies (6) Next 10 Prev Next

cowtown jay

Send PM Follow Ignore
Followers 89
Posts 6886
Boards Moderated 1
Alias Born 09/18/2009

cowtown jay

Re: cowtown jay post# 42731

Friday, 06/21/2024 6:15:18 PM

Friday, June 21, 2024 6:15:18 PM

Post# of 43443
"Humanigen Announces First Participant Dosed in RATinG Trial of Lenzilumab for Early Treatment of Acute Graft Versus Host Disease Following Allogeneic Stem Cell Transplantation
Aug 07, 2023...

Planned interim assessment expected in 2024 following treatment of first 20 participants"

https://ir.humanigen.com/English/news/news-details/2023/Humanigen-Announces-First-Participant-Dosed-in-RATinG-Trial-of-Lenzilumab-for-Early-Treatment-of-Acute-Graft-Versus-Host-Disease-Following-Allogeneic-Stem-Cell-Transplantation/default.aspx

"PREACH-M trial: Lenzilumab may improve treatment response in chronic myelomonocytic leukemia
Download PDF Copy

These results suggest lenzilumab may normalize hematologic and inflammatory aberrations in CMML and improve the condition of participants."

https://www.news-medical.net/news/20230609/PREACH-M-trial-Lenzilumab-may-improve-treatment-response-in-chronic-myelomonocytic-leukemia.aspx
Public Reply Private Reply New Post
Keep Last Read
Replies (6) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (6) Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up